Novartis signs five-year deal with Civica Rx on injectable medicines manufacturing
The agreement is aimed at helping to reduce essential drug shortages in the US
Novartis’ generics unit Sandoz has signed a long-term deal with non-profit pharma firm Civica Rx to manufacture and supply injectable generic medicines, to help reduce drug shortages in the US, the two companies announced on Tuesday.
Under the five-year agreement, Sandoz will supply six injectable medicines including antibiotics, acid reducers, blood thinners, blood pressure regulators and medicines required for operations which are all widely used at Civica’s 1,200 US member hospitals, to help ensure patients have access to high-quality, critical medicines when needed.
Initial supply is expected to begin shipping to Civica later this year.
“Frequent supply shortages of critical generic medicines result in additional pressure for hospitals and their staff and often lead to sub-optimal patient care,” said Carol Lynch, president of Sandoz.
"With Sandoz by our side, we will be able to stabilize the supply of more vital medicines used in hospitals daily and in times of crisis,” said Martin VanTrieste, president and CEO of Civica Rx.
Civica Rx’s hospital members to date include more than 50 health systems, representing 1,200 hospitals and more than 30 percent of all licensed US hospital beds.
Non-profit pharma firm Civica Rx will manufacture the finished dosage product on the same site as Phlow's precursor and API production and distribute via a network of more than 1,200 hospitals.
In late May, Civica, a generics maker started by hospitals fed up with rising drug prices, joined a Trump administration-funded initiative to produce a domestic generic supply of COVID-19 drugs.
In May, Civica signed up to a US government-funded initiative to manufacture generic COVID-19 treatments domestically.
Pharma start-up company Phlow Corporation won an eye-catching USD 354 million contract from the US government to manufacture generics and active pharmaceutical ingredients (APIs) needed for drugs in short supply, including COVID-19 treatments.
Under the terms of that agreement, Phlow is leading a team of private sector entities including Civica Rx and the Medicines for All Institute among others.
Civica Rx and its partners will manufacture finished dosage products of essential medicines, including vials and syringes.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance